Imatinib is a competitive inhibitor binding to the ATP active site of ABL1 that revolutionized the treatment of CML, but ∼30% of patients fail to achieve lasting results due to development of Imatinib resistance (3, 4). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.